AU2021103847A4 - Bismuthino for biomedicinal application and its analytical synthesis thereof - Google Patents
Bismuthino for biomedicinal application and its analytical synthesis thereof Download PDFInfo
- Publication number
- AU2021103847A4 AU2021103847A4 AU2021103847A AU2021103847A AU2021103847A4 AU 2021103847 A4 AU2021103847 A4 AU 2021103847A4 AU 2021103847 A AU2021103847 A AU 2021103847A AU 2021103847 A AU2021103847 A AU 2021103847A AU 2021103847 A4 AU2021103847 A4 AU 2021103847A4
- Authority
- AU
- Australia
- Prior art keywords
- bismuthino
- biomedicinal
- application
- bismuth
- aminophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 Bismuthino Chemical group 0.000 title claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 title abstract description 12
- 238000003786 synthesis reaction Methods 0.000 title abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- ZHTWCNXXCQSGGW-UHFFFAOYSA-N 4-bis(4-aminophenyl)bismuthanylaniline Chemical compound C1=CC(N)=CC=C1[Bi](C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 ZHTWCNXXCQSGGW-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000010668 complexation reaction Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- BMHUAWSZTBZHJO-UHFFFAOYSA-M 4-[(4-aminophenyl)-chlorobismuthanyl]aniline Chemical compound NC(C=C1)=CC=C1[Bi](C(C=C1)=CC=C1N)Cl BMHUAWSZTBZHJO-UHFFFAOYSA-M 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 238000002844 melting Methods 0.000 abstract description 5
- 230000008018 melting Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 238000000921 elemental analysis Methods 0.000 abstract description 3
- 230000003595 spectral effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 150000001622 bismuth compounds Chemical class 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229960004696 ranitidine bismuth citrate Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960004645 bismuth subcitrate Drugs 0.000 description 2
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- ILCQYORZHHFLNL-UHFFFAOYSA-N n-bromoaniline Chemical compound BrNC1=CC=CC=C1 ILCQYORZHHFLNL-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/94—Bismuth compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
BISMUTHINO FOR BIOMEDICINAL
APPLICATION AND ITS ANALYTICAL
SYNTHESIS THEREOF
ABSTRACT
The present invention relates to bismuthino for biomedicinal application
and its analytical synthesis thereof. The present invention concern with the design
and synthesis of a novel heterocyclic bismuthino and characterized analytically by
melting point, elemental analysis along with spectral techniques. The synthesized
compound show prominent biomedicinal activity.
15
Description
[001]. The present invention relates to the technical field of Field of
invention related to biomedicinal synthetic chemistry.
[002]. More particularly, the present invention is related to bismuthino for
biomedicinal application and its analytical synthesis thereof.
[003]. The subject matter discussed in the background section should not
be assumed to be prior art merely as a result of its mention in the background
section. Similarly, a problem mentioned in the background section or
associated with the subject matter of the background section should not be
assumed to have been previously recognized in the prior art. The subject
matter in the background section merely represents different approaches,
which in-and-of-themselves may also be inventions.
[004]. As per the latest research data about 85% of the compounds involved
in various organic synthesis focusing on the medicinal drugs comprises of
the heterocyclic moieties. Amidst the devastating effects implicated by the
corona virus covid -19 the compound hydroxychloroquine which belongs to
the heterocyclic compounds has been successful to some extent in providing
relief against the viral disease. Thus the exploration of the heterocyclic
scaffold as a powerful tool in the realms of clinical medicine is all the more
significant today. The organobismuth compounds have also attracted the
attention in this area owing to their microbiological and gastroprotective
utility. It was found that organobismuth compounds were active against the
treatment of gastrointestinal disorders like dyspepsia, diarrhea and in peptic
ulcers by inhibiting E. coli. The salts of organobismuth compounds, such as
colloidal bismuth sub-salicylate (CBS), bismuth sub-citrate (BSC) and
ranitidine bismuth citrate (RBC) are now common for controlling bacterial
and fungal infections. The ranitidine bismuth citrate, used as H2 antagonist
is an analog of histamine which involve in the control of gastric secretion.
The major advantage of bismuth compounds is their less toxicity and the Bi
C bond is biodegradable. The extensive chemical, biochemical,
biomedicinal and pharmacological studies of bismuth compounds have
enabled the medical applications of clinically used bismuth compounds to be extended. Bismuth compounds offer potentials in gastro-protection and cancer therapy not only by directly but also by indirectly reducing the side effect of the clinically used antiulcer and anticancer drugs..
[005]. Groupings of alternative elements or embodiments of the invention
disclosed herein are not to be construed as limitations. Each group member
can be referred to and claimed individually or in any combination with other
members of the group or other elements found herein. One or more members
of a group can be included in, or deleted from, a group for reasons of
convenience and/or patentability. When any such inclusion or deletion
occurs, the specification is herein deemed to contain the group as modified,
thus fulfilling the written description of all Markus groups used in the
appended claims. As used in the description herein and throughout the
claims that follow, the meaning of "a "an," and "the" includes plural
reference unless the context clearly dictates otherwise. Also, as used in the
description herein, the meaning of "in" includes "in" and "on" unless the
context clearly dictates otherwise.
[006]. The recitation of ranges of values herein is merely intended to serve
as a shorthand method of referring individually to each separate value
falling within the range. Unless otherwise indicated herein, each individual
value is incorporated into the specification as if it were individually recited
herein. All methods described herein can be performed in any suitable order
unless otherwise indicated herein or otherwise clearly contradicted by
context.
[007]. The use of any and all examples, or exemplary language (e.g. "Such
as") provided with respect to certain embodiments herein is intended merely
to better illuminate the invention and does not pose a limitation on the scope
of the invention otherwise claimed. No language in the specification should
be construed as indicating any non-claimed element essential to the practice
of the invention.
[008]. The above information disclosed in this Background section is only
for the enhancement of understanding of the background of the invention
and therefore it may contain information that does not form the prior art that
is already known in this country to a person of ordinary skill in the art.
[009]. Before the present systems and methods, are described, it is to be
understood that this application is not limited to the particular systems, and
methodologies described, as there can be multiple possible embodiments
which are not expressly illustrated in the present disclosure. It is also to be
understood that the terminology used in the description is for the purpose of
describing the particular versions or embodiments only and is not intended
to limit the scope of the present application.
[0010]. As aspect of present invention relates to a method for abismuthino
for biomedicinal application, wherein the method comprising steps of:
Preparating of Tris(p-aminophenyl)bismuth; Preparating of bis(p
aminophenyl)bismuth(III)chloride; and Performing a Complexation
Reaction, which includes In the stirring solution of bis(p
aminophenyl)bismuth(III)chloride(0.1mmol), 2-((4-((7-chloroquinolin-4
ylamino)pentyl)(ethyl)amino)ethanol (mmol) is added in presence of
triethylamine in benzene and is stirred in anhydrous oxygen free, nitrogen
conditions for some hour, followed by refluxing for to ensure completion
of the reaction, to obtain the bismuthino.
[0011]. The principle objective of the present invention is to provide an
bismuthino for biomedicinal application and its analytical synthesis thereof.
[0012]. To clarify various aspects of some example embodiments of the
present invention, a more particular description of the invention will be
rendered by reference to specific embodiments thereof which are illustrated
in the appended drawings. It is appreciated that these drawings depict only
illustrated embodiments of the invention and are therefore not to be
considered limiting of its scope. The invention will be described and
explained with additional specificity and detail through the use of the
accompanying drawings.
[0013]. In order that the advantages of the present invention will be easily
understood, a detailed description of the invention is discussed below in
conjunction with the appended drawings, which, however, should not be considered to limit the scope of the invention to the accompanying drawings, in which:
[0014]. Figure 1 shows formula of 2-((4-((bis(4
aminophenyl)bismuthino)(7-chloroquinolin-4
yl)amino)pentyl)(ethyl)amino)ethanol.
[0015]. Figure 2. Shows IR SPECTRA analysis.
[0016]. Figure 3. Shows NMR SPECTRA analysis.
[0017]. Figure 4. Shows Molecular Docking Studies.
[0018]. Figure 5. Shows unnamed ligand docking with target lactate
dehydrogenase (ldnA).
[0019]. The present invention is related to bismuthino for biomedicinal
application and its analytical synthesis thereof.
[0020]. Although the present disclosure has been described with the purpose
of bismuthino for biomedicinal application and its analytical synthesis
thereof, it should be appreciated that the same has been done merely to
illustrate the invention in an exemplary manner and to highlight any other purpose or function for which explained structures or configurations could be used and is covered within the scope of the present disclosure.
[0021]. Novel Synthesis:
[0022]. Different L.R. Grade solvent (BDH, SISCO, E. Merck and
RANBAXY) were used. Solvent purified and dried by conventional
methods prior to their use.
[0023]. The L.R. grade of Liquid amines, alcohols, benzenes etc of CDH
and SISCO were used without purification.
[0024]. All other chemicals (CDH, SISCO, E. Merck and RANBAXY)used,
were prior checked for their purities.
[0025]. The physiochemical techniques employed viz. melting point,
elemental analysis for carbon, hydrogen, nitrogen, infra-red (IR), mass and
nuclear magnetic resonance (NMR) spectra for characterization and
structure determination of compounds are performed by standard methods.
[0026]. The melting points for the synthesized compounds were determined
in open glass capillary tubes using a Khera instruments model no R1214
(220Volt/watt) melting point apparatus.
[0027]. The infrared (IR) spectra of the compounds were recorded in region
4000-400 cm-1 using KBr discs a Perkin-Elmer (Grating)
spectrophotometer model 337 at University of Lucknow, Lucknow.
[0028]. The nuclear magnetic resonance (NMR) studies were carried out on
at 800 MHz NMR Spectrometer (Make: Bruker GmbH, Germany Model:
AVANCE III equipped with Cryoprobe) at Center of Biomedical Research
(CBMR) SGPGI, Lucknow using CDCl3 or DMSO as solvent. In all the
cases trimethylsilane (TMS) were used as an internal indicator and the
values of chemical shift were given in -scales.
[0029]. Mostly, all compounds were dried finally in vacuum desiccators.
[0030]. The molecular docking studies were performed by standard software
of computational studies.
[0031]. Novel Route of Synthesis:
[0032]. 1. Preparation of Tris(p-aminophenyl)bismuth: A solution of
bismuth trichloride (0.Imol) and bromoaniline (0.Imol) in benzene (200 ml)
was added drop wise to a boiling suspension of sodium (0.6mol) in the same
solvent (300 ml). The reaction mixture was refluxed for 5 hr with occasional
shaking and then filtered hot. The residue was extracted twice with hot
benzene. The solvent was completely distilled off and the remaining residue
was recrystallised from alcohol/pet-ether (60-800) mixture. Yield - (78%)
[0033]. 2. Preparation of bis(p-aminophenyl)bismuth(III)chloride: This
reaction involves the use of metal halides and an organometallic compound
in presence of or in absence of an appropriate solvent (neat/without solvent).
The formation of the compounds can be represented in the form of equation
shown below.
[0034]. 2R3Bi+BiCl3 0 3R2BiCl
[0035]. Tris (p-aminophenyl) bismuth (2mmol) and bismuth trichloride
(immol) on mixing followed by shaking are rapidly liquefied and
redistribution was completed in about three hour at 25oC. The off white
color viscous oil of the compound was crystallized from dichloromethane
and diethyl ether.
[0036]. 3. Complexation Reaction: In the stirring solution of bis(p
aminophenyl)bismuth(III)chloride(0.1mmol), 2-((4-((7-chloroquinolin-4
ylamino)pentyl)(ethyl)amino)ethanol(mmol) was added in presence of
triethylamine (1 ml) in benzene and was stirred in anhydrous oxygen free,
nitrogen conditions for 6h, followed by refluxing for 2h to ensure
completion of the reaction. A flocculent white precipitate of Et3N.HCl
(M.P.240°C) was formed which was filtered off. The filtrate on
concentration gave a light brown solid which was recrystallised by
petroleum ether (40°-60°C).
[0037].
[0038]. 2-((4-((bis(4-aminophenyl)bismuthino)(7-chloroquinolin-4
yl)amino)pentyl)(ethyl)amino)ethanol
[0039]. Molecular Formula: C30H37BiClN50
[0040]. Molecular weight: 727.25
[0041]. Melting Point: 166°C
[0042]. Elemental Analysis: C = 49.49; H = 5.12; N = 9.62;
unnamedligand docking with target lactate dehydrogenase (1ldnA)
Binding Binding LigPlot + H Target/Ligand Energy Affinity Bond Image
l1dn_A_unnamed-ligand E=904.23 -7 3
[0043]. The figures and the foregoing description give examples of
embodiments. Those skilled in the art will appreciate that one or more of
the described elements may well be combined into a single functional
element. Alternatively, certain elements may be split into multiple
functional elements. Elements from one embodiment may be added to
another embodiment. For example, order of processes described herein may
be changed and are not limited to the manner described herein. Moreover,
the actions of any flow diagram need not be implemented in the order
shown; nor do all of the acts need to be necessarily performed. Also, those acts that are not dependent on other acts may be performed in parallel with the other acts. The scope of embodiments is by no means limited by these specific examples.
[0044]. Although implementations of the invention have been described in
a language specific to structural features and/or methods, it is to be
understood that the appended claims are not necessarily limited to the
specific features or methods described. Rather, the specific features and
methods are disclosed as examples of implementations of the invention.
Claims (2)
1. A method for a bismuthino for biomedicinal application,
wherein the method comprising steps of:
Preparating of Tris(p-aminophenyl)bismuth;
Preparating of bis(p-aminophenyl)bismuth(III)chloride; and
Performing a Complexation Reaction, which includes In the
stirring solution of bis(p
aminophenyl)bismuth(III)chloride(O.1mmol), 2-((4-((7
chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol (1mmol)
is added in presence of triethylamine in benzene and is stirred in
anhydrous oxygen free, nitrogen conditions for some hour followed by refluxing for to ensure completion of the reaction, to obtain the bismuthino.
2. A bismuthino for biomedicinal application, wherein bismuthino
is of formula of X,
H 2N
N OH N
Wherein X
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021103847A AU2021103847A4 (en) | 2021-07-03 | 2021-07-03 | Bismuthino for biomedicinal application and its analytical synthesis thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021103847A AU2021103847A4 (en) | 2021-07-03 | 2021-07-03 | Bismuthino for biomedicinal application and its analytical synthesis thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021103847A4 true AU2021103847A4 (en) | 2021-09-09 |
Family
ID=77563849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021103847A Ceased AU2021103847A4 (en) | 2021-07-03 | 2021-07-03 | Bismuthino for biomedicinal application and its analytical synthesis thereof |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021103847A4 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122470A1 (en) * | 2021-12-21 | 2023-06-29 | Versum Materials Us, Llc | Precursors for deposition of bismuth-containing films |
-
2021
- 2021-07-03 AU AU2021103847A patent/AU2021103847A4/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122470A1 (en) * | 2021-12-21 | 2023-06-29 | Versum Materials Us, Llc | Precursors for deposition of bismuth-containing films |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hagadorn et al. | Tethered bis‐amidinates as supporting ligands: A concerted elimination/σ–π rearrangement reaction forming an unusual titanium arene complex | |
| Huang et al. | Synthesis, characterization and antitumor activity of novel ferrocene derivatives containing pyrazolyl-moiety | |
| Beyer et al. | Preparation, characterization and properties of dipolar 1, 2-N, N-dimethylaminomethylferrocenylsilanes | |
| Takeuchi et al. | Highly regioselective allylic alkylation of dienyl acetates and enynyl acetates catalyzed by an iridium complex | |
| Casas et al. | Zinc (II), cadmium (II) and mercury (II) complexes of the vitamin B1 antagonist oxythiamine | |
| AU2021103847A4 (en) | Bismuthino for biomedicinal application and its analytical synthesis thereof | |
| CA2473075A1 (en) | Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives | |
| Peters et al. | Complexes bearing an enantiopure N, N, O scorpionate ligand derived from (−)-menthone | |
| Güven Kuzey et al. | Phosphorus–nitrogen compounds Part 55. Syntheses of 4-methoxybenzylspiro (N/N) cyclotriphosphazenes: chemical, structural and biological properties | |
| Bembi et al. | Polyazamacrocycles. 9. Characterization of diastereoisomeric trans-[Co (Me8 [14] ane) Cl2]+ complexes | |
| Ciobanu et al. | First dinuclear B (II) monocations with bridging guanidinate ligands: synthesis and properties | |
| Zhou et al. | Novel Rearrangement Reactions. 1. Molecular Rearrangement via Metathesis between Intramolecular Si− Si and Fe− Fe Bonds | |
| Hajela et al. | Synthesis of homochiral tris (2-alkyl-2-aminoethyl) amine derivatives from chiral α-amino aldehydes and their application in the synthesis of water soluble chelators | |
| Andrieu et al. | Synthesis, coordination to Rh (I), and hydroformylation catalysis of new β-aminophosphines bearing a dangling nitrogen group: An unusual inversion of a Rh-coordinated P center | |
| WO2021220043A1 (en) | Method of synthesis and biomedicinal applications of novel heterocyclic bismuthine | |
| Dialer et al. | α‐Amino Acids with Metallocenyl Side Chains | |
| CN105503977A (en) | 1,3,4-oxadiazole derivative containing glucosamine molecules and preparation method and application thereof | |
| Necas et al. | The synthesis and characterisation of bis (diisopropylphosphoryl) ferrocene Fe [(η5-C5H4) P (O) iPr2] 2, bis (diisopropylthiophosphoryl) ferrocene Fe [(η5-C5H4) P (S) iPr2] 2, and bis (diisopropylselenophosphoryl) ferrocene Fe [(η5-C5H4) P (Se) iPr2] 2, the oxidised derivatives of bis (diisopropylphosphino) ferrocene | |
| CN1329400C (en) | Dicarba-closo-dodecaborane derivatives | |
| Gusarova et al. | Diselenophosphinates of lupinine or anabasine via a new three-component reaction of secondary phosphines, elemental selenium, and amines | |
| Mercier et al. | 1-Phosphanorbornadiene-imines and amines in enantioselective allylic C-and N-alkylation | |
| Dkhar et al. | Cp and indenyl ruthenium complexes containing dithione derivatives: Synthesis, antibacterial and antifungal study | |
| Obijalska et al. | Synthesis of Three‐, Five‐, and Six‐Membered Heterocycles Derived from New β‐Amino‐α‐(trifluoromethyl) Alcohols | |
| Wuckelt et al. | Regioselective Synthesis of 5-Ylidenepyrrol-2 (5 H)-ones by Reaction of Transition Metal-Coordinated Bis (imidoyl) Chlorides with Carbon Nucleophiles | |
| Löhnwitz et al. | Aminotroponiminate zinc complexes with different leaving groups as catalysts for the intramolecular hydroamination of alkenes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |